Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer Academic Article uri icon

Overview

MeSH Major

  • Abiraterone Acetate
  • Antineoplastic Agents, Hormonal
  • Antineoplastic Combined Chemotherapy Protocols
  • Bone Density Conservation Agents
  • Bone Neoplasms
  • Prostatic Neoplasms, Castration-Resistant
  • Steroid Synthesis Inhibitors

abstract

  • We assessed adverse events in patients with metastatic castration-resistant prostate cancer during long-term treatment with a low dose of a corticosteroid. We found that long-term treatment with this low-dose corticosteroid is safe and tolerable.

publication date

  • January 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5570464

Digital Object Identifier (DOI)

  • 10.1016/j.eururo.2016.02.035

PubMed ID

  • 26965562

Additional Document Info